These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 34475315)

  • 1. Polymyxins, the last-resort antibiotics: Mode of action, resistance emergence, and potential solutions.
    Mohapatra SS; Dwibedy SK; Padhy I
    J Biosci; 2021; 46(3):. PubMed ID: 34475315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort.
    Ledger EVK; Sabnis A; Edwards AM
    Microbiology (Reading); 2022 Feb; 168(2):. PubMed ID: 35118938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. History, Chemistry and Antibacterial Spectrum.
    Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ
    Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug-Resistant Gram-Negative Pathogens: The Urgent Need for 'Old' Polymyxins.
    Paterson DL; Bonomo RA
    Adv Exp Med Biol; 2019; 1145():9-13. PubMed ID: 31364068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes.
    Almangour TA; Garcia E; Zhou Q; Forrest A; Kaye KS; Li J; Velkov T; Rao GG
    Int J Antimicrob Agents; 2021 Jun; 57(6):106328. PubMed ID: 33785362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
    Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Janet-Maitre M; Job V; Bour M; Robert-Genthon M; Brugière S; Triponney P; Cobessi D; Couté Y; Jeannot K; Attrée I
    mBio; 2024 Mar; 15(3):e0221123. PubMed ID: 38345374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel derivatives of polymyxins.
    Vaara M
    J Antimicrob Chemother; 2013 Jun; 68(6):1213-9. PubMed ID: 23412346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of bactericidal action and resistance of polymyxins for Gram-positive bacteria.
    Yin J; Meng Q; Cheng D; Fu J; Luo Q; Liu Y; Yu Z
    Appl Microbiol Biotechnol; 2020 May; 104(9):3771-3780. PubMed ID: 32157424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rescuing the Last-Line Polymyxins: Achievements and Challenges.
    Nang SC; Azad MAK; Velkov T; Zhou QT; Li J
    Pharmacol Rev; 2021 Apr; 73(2):679-728. PubMed ID: 33627412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to polymyxins in Gram-negative organisms.
    Jeannot K; Bolard A; Plésiat P
    Int J Antimicrob Agents; 2017 May; 49(5):526-535. PubMed ID: 28163137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Polymyxin Resistance.
    Moffatt JH; Harper M; Boyce JD
    Adv Exp Med Biol; 2019; 1145():55-71. PubMed ID: 31364071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outer Membranes of Polymyxin-Resistant
    Jiang X; Yang K; Han ML; Yuan B; Li J; Gong B; Velkov T; Schreiber F; Wang L; Li J
    ACS Infect Dis; 2020 Oct; 6(10):2698-2708. PubMed ID: 32871077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane-targeting, ultrashort lipopeptide acts as an antibiotic adjuvant and sensitizes MDR gram-negative pathogens toward narrow-spectrum antibiotics.
    Panjla A; Kaul G; Shukla M; Akhir A; Tripathi S; Arora A; Chopra S; Verma S
    Biomed Pharmacother; 2024 Jul; 176():116810. PubMed ID: 38823276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component.
    Domalaon R; Berry L; Tays Q; Zhanel GG; Schweizer F
    Bioorg Chem; 2018 Oct; 80():639-648. PubMed ID: 30053708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymyxin susceptibility testing, interpretative breakpoints and resistance mechanisms: An update.
    Bakthavatchalam YD; Pragasam AK; Biswas I; Veeraraghavan B
    J Glob Antimicrob Resist; 2018 Mar; 12():124-136. PubMed ID: 28962863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.
    Velkov T; Roberts KD; Nation RL; Thompson PE; Li J
    Future Microbiol; 2013 Jun; 8(6):711-24. PubMed ID: 23701329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
    Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
    Falagas ME; Kasiakou SK
    Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H; Poulakou G
    Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.